furylfuramide has been researched along with Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouvier, M; Diennet, M; El Ezzy, M; Haidar, S; Mader, S; Vallet, A | 1 |
| SCALONE, I | 1 |
2 other study(ies) available for furylfuramide and Breast Cancer
| Article | Year |
|---|---|
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Furylfuramide; Humans; Ligands; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Sumoylation; Tamoxifen | 2023 |
[Results of treatment with factor AF-2 in 656 cases of inoperable cancer of the breast].
Topics: Breast; Breast Neoplasms; Furylfuramide; Humans; Neoplasms | 1950 |